These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 30052921)

  • 1. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 2. [Not Available].
    Fischli S; Henzen C
    Ther Umsch; 2017; 74(8):433-439. PubMed ID: 29461151
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?
    Lehmann EW; Torekov SS
    Cardiovasc Res; 2021 Aug; 117(10):e120-e122. PubMed ID: 34448813
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.
    Sodhi M; Rezaeianzadeh R; Kezouh A; Etminan M
    JAMA; 2023 Nov; 330(18):1795-1797. PubMed ID: 37796527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
    Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
    Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semaglutide (Ozempic) for weight loss.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):53-54. PubMed ID: 33830968
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.
    Boyle JG; Livingstone R; Petrie JR
    Clin Sci (Lond); 2018 Aug; 132(15):1699-1709. PubMed ID: 30115742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Jan; 60(1539):19-21. PubMed ID: 29364197
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
    Athyros VG; Katsiki N; Tentolouris N
    Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
    [No Abstract]   [Full Text] [Related]  

  • 12. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms.
    Rizzo M; Nikolic D; Patti AM; Mannina C; Montalto G; McAdams BS; Rizvi AA; Cosentino F
    Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2814-2821. PubMed ID: 29778663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
    Kaplan JM; Zaman A; Abushamat LA
    Curr Cardiol Rep; 2024 Sep; 26(9):1011-1019. PubMed ID: 39031282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Effects of Liraglutide.
    Mikhail N
    Curr Hypertens Rev; 2019; 15(1):64-69. PubMed ID: 29737256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
    Sposito AC; Berwanger O; de Carvalho LSF; Saraiva JFK
    Cardiovasc Diabetol; 2018 Dec; 17(1):157. PubMed ID: 30545359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 receptor agonists and cardiovascular outcome trials: An update.
    Andrikou E; Tsioufis C; Andrikou I; Leontsinis I; Tousoulis D; Papanas N
    Hellenic J Cardiol; 2019; 60(6):347-351. PubMed ID: 30528435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
    Peterson SC; Barry AR
    Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Christensen RM; Juhl CR; Torekov SS
    Drug Saf; 2019 Aug; 42(8):957-971. PubMed ID: 30972641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.